Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~31 mi. (West Woodlands, United Kingdom, +163 more cities)

Walsall Manor Hospital-Oncology ( Site 0743)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

~33 mi. (Southampton, United Kingdom, +108 more cities)

Southampton General Hospital

Germ Cell Tumor

carboplatin, +5 more drugs

chemotherapy, +1 more type

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

~33 mi. (Southampton, United Kingdom, +118 more cities)

Southampton General Hospital

NTRK1 Fusion, +2 more biomarkers

Biliary Tract Carcinoma, +12 more conditions

larotrectinib

targeted therapy

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

~33 mi. (Southampton, United Kingdom, +54 more cities)

University Hospital Southampton NHS Foundation Trust /ID# 228332

Multiple Myeloma

carfilzomib, +4 more drugs

chemotherapy, +3 more types

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

~33 mi. (Southampton, United Kingdom, +21 more cities)

University Hospital Southampton NHS Foundation Trust

Bladder Urothelial Carcinoma

durvalumab

immunotherapy

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

~33 mi. (Southampton, United Kingdom, +5 more cities)

Southampton General Hospital

ERBB2 Amplification, +2 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +3 more conditions

BAY2701438, +1 more drug

radiation therapy, +1 more type

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

~33 mi. (Southampton, United Kingdom, +34 more cities)

GSK Investigational Site

Multiple Myeloma

belantamab mafodotin, +3 more drugs

chemotherapy, +2 more types

PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

~36 mi. (Swindon, United Kingdom, +7 more cities)

Great Western Hospital

ER Positive, +1 more biomarker

Invasive Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~38 mi. (Bath, United Kingdom, +356 more cities)

Royal United Hospital Bath NHS Trust - Royal United Hospital RUH

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer

~43 mi. (Bournemouth, United Kingdom, +8 more cities)

Royal Bournemouth Hospital

ER Negative, +2 more biomarkers

Invasive Breast Carcinoma

ceralasertib, +2 more drugs

immunotherapy, +1 more type

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

~44 mi. (Poole, United Kingdom, +86 more cities)

Dorset Cancer Centre Poole Hospital

Follicular Lymphoma, +4 more conditions

lutetium Lu 177 lilotomab-satetraxetan, +1 more drug

chemotherapy, +2 more types

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~54 mi. (Bristol, United Kingdom, +226 more cities)

University Hospitals Bristol NHS Foundation Trust ( Site 0530)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type